메뉴 건너뛰기




Volumn 115, Issue 22, 2009, Pages 5339-5348

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group

Author keywords

Children's Oncology Group; Metastatic osteosarcoma; Muramyl tripeptide; Survival

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; PHOSPHATIDYLETHANOLAMINE;

EID: 70449369314     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24566     Document Type: Article
Times cited : (220)

References (27)
  • 1
    • 34247140972 scopus 로고    scopus 로고
    • Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: Children's Cancer Group (CCG) 7943
    • Seibel NL, Krailo M, Chen Z, et al. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943. Cancer. 2007;109:1646-1653.
    • (2007) Cancer , vol.109 , pp. 1646-1653
    • Seibel, N.L.1    Krailo, M.2    Chen, Z.3
  • 2
    • 33644505791 scopus 로고    scopus 로고
    • Prognostic factors for osteosarcoma of the extremity trerated with neoadjuvant chemotherapy: 15-Year experience in 789 patients treated at a single institution
    • DOI 10.1002/cncr.21724
    • Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154-1161. (Pubitemid 43297356)
    • (2006) Cancer , vol.106 , Issue.5 , pp. 1154-1161
    • Bacci, G.1    Longhi, A.2    Versari, M.3    Mercuri, M.4    Briccoli, A.5    Picci, P.6
  • 4
    • 32044438250 scopus 로고    scopus 로고
    • A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma
    • DOI 10.1002/pbc.20562
    • McTiernan A, Meyer T, Michelagnoli MP, Lewis I, Whelan JS. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. Pediatr Blood Cancer. 2006;46:345-350. (Pubitemid 43201851)
    • (2006) Pediatric Blood and Cancer , vol.46 , Issue.3 , pp. 345-350
    • McTiernan, A.1    Meyer, T.2    Michelagnoli, M.P.3    Lewis, I.4    Whelan, J.S.5
  • 6
    • 12944305738 scopus 로고    scopus 로고
    • Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only
    • DOI 10.1097/01.mph.0000150739.73067.f3
    • del Prever AB, Fagioli F, Berta M, Bertoni F, Ferrari S, Mercuri M. Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only. J Pediatr Hematol Oncol. 2005;27:42-45. (Pubitemid 40175961)
    • (2005) Journal of Pediatric Hematology/Oncology , vol.27 , Issue.1 , pp. 42-45
    • Del Prever, A.B.1    Fagioli, F.2    Berta, M.3    Bertoni, F.4    Ferrari, S.5    Mercuri, M.6
  • 7
    • 0038688477 scopus 로고    scopus 로고
    • Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols
    • Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011-2018.
    • (2003) J Clin Oncol , vol.21 , pp. 2011-2018
    • Kager, L.1    Zoubek, A.2    Potschger, U.3
  • 8
    • 0041700123 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: Recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide
    • Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003;14:1126-1134.
    • (2003) Ann Oncol , vol.14 , pp. 1126-1134
    • Bacci, G.1    Briccoli, A.2    Rocca, M.3
  • 10
    • 0027383879 scopus 로고
    • Liposome-encapsulated MTP-PE: A novel biologic agent for cancer therapy
    • Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother Emphasis Tumor Immunol. 1993;14:286-292.
    • (1993) J Immunother Emphasis Tumor Immunol , vol.14 , pp. 286-292
    • Asano, T.1    Kleinerman, E.S.2
  • 11
    • 0024359271 scopus 로고
    • Therapy for osteosarcoma in dogs with intravenous injection of liposome- encapsulated muramyl tripeptide
    • MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome- encapsulated muramyl tripeptide. J Natl Cancer Inst. 1989;81:935-938.
    • (1989) J Natl Cancer Inst , vol.81 , pp. 935-938
    • MacEwen, E.G.1    Kurzman, I.D.2    Rosenthal, R.C.3
  • 12
    • 0026631061 scopus 로고
    • Phase II study of liposomal muramyl tripeptide in osteosarcoma: The cytokine cascade and monocyte activation following administration
    • Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992;10:1310-1316.
    • (1992) J Clin Oncol , vol.10 , pp. 1310-1316
    • Kleinerman, E.S.1    Jia, S.F.2    Griffin, J.3    Seibel, N.L.4    Benjamin, R.S.5    Jaffe, N.6
  • 13
    • 0027347270 scopus 로고
    • Liposome-encapsulated muramyl tripeptide: A new biologic response modifier for the treatment of osteosarcoma
    • Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res. 1993;62:101-107.
    • (1993) Cancer Treat Res , vol.62 , pp. 101-107
    • Kleinerman, E.S.1    Maeda, M.2    Jaffe, N.3
  • 14
    • 20244387692 scopus 로고
    • Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: A progress review
    • MacEwen EG, Kurzman ID, Helfand S, et al. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Target. 1994;2:391-396.
    • (1994) J Drug Target , vol.2 , pp. 391-396
    • MacEwen, E.G.1    Kurzman, I.D.2    Helfand, S.3
  • 15
    • 0029125936 scopus 로고
    • Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide
    • Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am. 1995;9:927-938.
    • (1995) Hematol Oncol Clin North Am , vol.9 , pp. 927-938
    • Kleinerman, E.S.1
  • 16
    • 0028928375 scopus 로고
    • Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma
    • Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995;18:93-99.
    • (1995) Am J Clin Oncol , vol.18 , pp. 93-99
    • Kleinerman, E.S.1    Gano, J.B.2    Johnston, D.A.3    Benjamin, R.S.4    Jaffe, N.5
  • 17
    • 0028997131 scopus 로고
    • Combination therapy with ifosfamide and liposome- encapsulated muramyl tripeptide: Tolerability, toxicity, and immune stimulation
    • Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N. Combination therapy with ifosfamide and liposome- encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol. 1995;17:181-193.
    • (1995) J Immunother Emphasis Tumor Immunol , vol.17 , pp. 181-193
    • Kleinerman, E.S.1    Meyers, P.A.2    Raymond, A.K.3    Gano, J.B.4    Jia, S.F.5    Jaffe, N.6
  • 18
    • 0032916105 scopus 로고    scopus 로고
    • In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells
    • Kurzman ID, Shi F, Vail DM, MacEwen EG. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Cancer Biother Radiopharm. 1999;14:121-128.
    • (1999) Cancer Biother Radiopharm , vol.14 , pp. 121-128
    • Kurzman, I.D.1    Shi, F.2    Vail, D.M.3    MacEwen, E.G.4
  • 19
    • 33745492007 scopus 로고    scopus 로고
    • Liposomal muramyl tripeptide phosphatidyl ethanolamine: Ifosfamide-containing chemotherapy in osteosarcoma
    • DOI 10.2217/14796694.2.3.333
    • Anderson P. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol. 2006;2:333-343. (Pubitemid 43960105)
    • (2006) Future Oncology , vol.2 , Issue.3 , pp. 333-343
    • Anderson, P.1
  • 20
    • 33745642092 scopus 로고    scopus 로고
    • Novel therapeutic approaches in pediatric and young adult sarcomas
    • Anderson PM, Pearson M. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep. 2006;8:310-315. (Pubitemid 43970983)
    • (2006) Current Oncology Reports , vol.8 , Issue.4 , pp. 310-315
    • Anderson, P.M.1    Pearson, M.2
  • 21
    • 33645828043 scopus 로고    scopus 로고
    • Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma
    • Nardin A, Lefebvre ML, Labroquere K, Faure O, Abastado JP. Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets. 2006;6:123-133.
    • (2006) Curr Cancer Drug Targets , vol.6 , pp. 123-133
    • Nardin, A.1    Lefebvre, M.L.2    Labroquere, K.3    Faure, O.4    Abastado, J.P.5
  • 22
    • 39149136228 scopus 로고    scopus 로고
    • Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group
    • Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol. 2008;26:633-638.
    • (2008) J Clin Oncol , vol.26 , pp. 633-638
    • Meyers, P.A.1    Schwartz, C.L.2    Krailo, M.D.3
  • 23
    • 20144380941 scopus 로고    scopus 로고
    • Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
    • Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
    • (2005) J Clin Oncol , vol.23 , pp. 2004-2011
    • Meyers, P.A.1    Schwartz, C.L.2    Krailo, M.3
  • 25
    • 0242440867 scopus 로고    scopus 로고
    • Osteosarcoma Necrosis Following Chemotherapy: Innate Biology Versus Treatment-Specific
    • DOI 10.1097/00043426-200311000-00003
    • Gorlick R, Meyers PA. Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J Pediatr Hematol Oncol. 2003;25:840-841. (Pubitemid 37413831)
    • (2003) Journal of Pediatric Hematology/Oncology , vol.25 , Issue.11 , pp. 840-841
    • Gorlick, R.1    Meyers, P.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.